RYAM indefinitely suspended operations at its Temiscaming cellulose plant in July 2024 to mitigate capital needs and operating losses from commodity viscose exposure.
The plant closure represents a significant operational restructuring as the company retreats from commodity viscose products to focus on higher-margin cellulose specialties. This strategic pivot, while potentially beneficial long-term, has created substantial near-term financial strain as evidenced by the dramatic decline in operating performance and cash generation.
RYAM's financial performance deteriorated substantially in 2025, with operating income declining dramatically and operating cash flow falling significantly from $203.6M to $23.9M. Gross profit decreased meaningfully by 28.3% while the company increased capital expenditures and R&D spending. The balance sheet shows the strain from operational challenges, with stockholders' equity declining by over half to $316.6M and cash reserves dropping to $75.4M, reflecting the financial impact of the plant closure and operational restructuring.
Dividend payments increased 99.4% — management confidence in sustained cash generation.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Operating cash flow fell 88.3% — earnings quality concerns; investigate working capital changes and non-cash items.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
R&D investment increased 40% — signals commitment to future product development, though near-term margin impact.
Cash declined 39.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
Capex increased 23.4% — ongoing investment in capacity or infrastructure for future growth.
Total assets contracted 17.4% — asset sales, write-downs, or balance sheet optimization underway.
Inventory built 14.4% — monitor whether demand supports this build or if write-downs may follow.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →